menu_open Columnists
We use cookies to provide some features and experiences in QOSHE

More information  .  Close

Can South Africa Tackle HIV Without the U.S.?

1 0
yesterday

U.S. State Department

Two years ago, Linda-Gail Bekker was jubilant. She had just led a major clinical trial in South Africa, the epicenter of the global HIV epidemic, testing a new form of prevention that was astonishingly effective. The drug, lenacapavir, is a pre-exposure prophylaxis (PrEP), which blocks the virus from spreading in HIV-negative people. A twice-yearly injection could replace daily pills, offering longer-lasting protection and thus slowing the spread of the virus.

When Bekker, the CEO of the Desmond Tutu Health Foundation in Cape Town, South Africa, announced the results of her trial at the International AIDS Conference in Munich in July 2024, the room erupted in a standing ovation. “There was huge anticipation and excitement. And then January came around, and suddenly that all disappeared,” she said, referring to the start of U.S. President Donald Trump’s second term.

Two years ago, Linda-Gail Bekker was jubilant. She had just led a major clinical trial in South Africa, the epicenter of the global HIV epidemic, testing a new form of prevention that was astonishingly effective. The drug, lenacapavir, is a pre-exposure prophylaxis (PrEP), which blocks the virus from spreading in HIV-negative people. A twice-yearly injection could replace daily pills, offering longer-lasting protection and thus slowing the spread of the virus.

When Bekker, the CEO of the Desmond Tutu Health Foundation in Cape Town, South Africa, announced the results of her trial at the International AIDS Conference in Munich in July 2024, the room erupted in a standing ovation. “There was huge anticipation and excitement. And then January came around, and suddenly that all disappeared,” she said, referring to the start of U.S. President Donald Trump’s second term.

The Trump administration took a chainsaw to global health programs, including the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), which has provided around $8 billion to South Africa since 2003. South Africa pays for most of its own HIV programs, including 90 percent of its antiretroviral drugs. Still, the collapse of PEPFAR was devastating, shuttering clinics for high-risk groups and leaving thousands of health workers without jobs.

South Africa is home to around 8 million people living with HIV, or around 20 percent of the global HIV population. Approximately 6 million of them are on treatment, but the country still records around 170,000 new infections each year.

When South Africa began rolling out lenacapavir this summer, the landscape had changed dramatically. U.S.-South Africa relations have deteriorated, as Trump has objected to South Africa’s genocide case against Israel in the International Court of Justice and accused the country of committing genocide against white Afrikaners. Those tensions have compounded uncertainty for the HIV program.

Last year, the United States provided South Africa with $115 million to keep core HIV services running, but in June, the Trump administration said it would end all PEPFAR funding for the country in the coming months. Washington also excluded South Africa from global health financing deals struck this year with........

© Foreign Policy